Arrowhead Pharmaceuticals Announces Multiple Presentations at The International Liver Congress™

Arrowhead Pharmaceuticals Announces...

PASADENA, Calif.–(BUSINESS WIRE)–Mar. 28, 2018–
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it
will present clinical and pre-clinical data on the company’s
investigational medicines for the treatment of chronic hepatitis B
infection (ARC-520 and ARO-HBV) and liver disease associated with
alpha-1 antitrypsin deficiency (ARO-AAT), at The International Liver
Congress™ 2018, the annual meeting of the European Association for the
Study of the Liver (EASL), being held in Paris from April 11-15, 2018.

Oral Presentations:

Development of subcutaneously administered RNAi therapeutic ARO-HBV
for chronic hepatitis B virus infection

Presentation Reference: PS-030
Session: Parallel session: Parallel session: HBV Cure: Pre-clinical
studies
Date and Time: April 12, 2018 at 5:15 p.m. CET
Authors: Christine Wooddell, et al.

ARO-AAT, a subcutaneous RNAi-based therapeutic for alpha-1
antitrypsin-related liver disease, demonstrates liver exposure-response
and efficacy in preclinical studies

Presentation Reference: PS-147
Session: Parallel session: Clinical developments in metabolic and rare
disease
Date and Time: April 14, 2018 at 9:15 a.m. CET
Authors: Christine Wooddell, et al.

Poster Presentation:

RNA interference therapy with ARC-520 Injection results in long term
off-therapy antigen reductions in treatment naïve, HBeAg positive and
negative patients with chronic HBV

Presentation Reference: FRI-362
Session: Viral hepatitis B/D: Therapy
Session Date and Time: April 13, 2018 from 9 a.m. to 5 p.m. CET
Authors: Man-Fung Yuen, et al.

Additional details, including presentation abstracts, can be found on
the ILC website at https://ilc-congress.eu/.
A copy of presentation materials can be accessed by visiting the Events
section of the Arrowhead website after the presentations conclude.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable
diseases by silencing the genes that cause them. Using a broad portfolio
of RNA chemistries and efficient modes of delivery, Arrowhead therapies
trigger the RNA interference mechanism to induce rapid, deep, and
durable knockdown of target genes. RNA interference, or RNAi, is a
mechanism present in living cells that inhibits the expression of a
specific gene, thereby affecting the production of a specific protein.
Arrowhead’s RNAi-based therapeutics leverage this natural pathway of
gene silencing.

For more information, please visit www.arrowheadpharma.com,
or follow us on Twitter @ArrowheadPharma.
To be added to the Company’s email list and receive news directly,
please visit http://ir.arrowheadpharma.com/email-alerts.

Safe Harbor Statement under the Private Securities Litigation Reform
Act:

This news release contains forward-looking statements within the
meaning of the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based upon our
current expectations and speak only as of the date hereof. Our actual
results may differ materially and adversely from those expressed in any
forward-looking statements as a result of various factors and
uncertainties, including the safety and efficacy of our product
candidates, the duration and impact of regulatory delays in our clinical
programs, our ability to finance our operations, the future success of
our scientific studies, our ability to successfully develop drug
candidates, the timing for starting and completing clinical trials,
rapid technological change in our markets, and the enforcement of our
intellectual property rights. Our most recent Annual Report on Form 10-K
and subsequent Quarterly Reports on Form 10-Q discuss some of the
important risk factors that may affect our business, results of
operations and financial condition. We assume no obligation to update or
revise forward-looking statements to reflect new events or circumstances.

Source: Arrowhead Pharmaceuticals, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180328005313/en/

Source: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA, 626-304-3400
ir@arrowheadpharma.com
or
Investors
and Media:
LifeSci Advisors, LLC
Brian Ritchie,
212-915-2578
britchie@lifesciadvisors.com
www.lifesciadvisors.com